Rational Prescribing in Primary Care (RaPP): Economic Evaluation of an Intervention to Improve Professional Practice
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Interventions designed to narrow the gap between research findings and clinical practice may be effective, but also costly. Economic evaluations are necessary to judge whether such interventions are worth the effort. We have evaluated the economic effects of a tailored intervention to support the implementation of guidelines for the use of antihypertensive and cholesterol-lowering drugs. The tailored intervention was evaluated in a randomized trial, and was shown to significantly increase the use of thiazides for patients started on antihypertensive medication, but had little or no impact on other outcomes. The increased use of thiazides was not expected to have an impact on health outcomes. METHODS AND FINDINGS: We performed cost-minimization and cost-effectiveness analyses on data from a randomized trial involving 146 general practices from two geographical areas in Norway. Each practice was randomized to either the tailored intervention (70 practices; 257 physicians) or control group (69 practices; 244 physicians). Only patients that were being started on antihypertensive medication were included in the analyses. A multifaceted intervention was tailored to address identified barriers to change. Key components were an educational outreach visit with audit and feedback, and computerized reminders. Pharmacists conducted the visits. A cost-minimization framework was adopted, where the costs of intervention were set against the reduced treatment costs (principally due to increased use of thiazides rather than more expensive medication). The cost-effectiveness of the intervention was estimated as the cost per additional patient being started on thiazides. The net annual cost (cost minimization) in our study population was 53,395 US dollars, corresponding to 763 US dollars per practice. The cost per additional patient started on thiazides (cost-effectiveness) was 454 US dollars. The net annual savings in a national program was modeled to be 761,998 US dollars, or 540 US dollars per practice after 2 y. In this scenario the savings exceeded the costs in all but two of the sensitivity analyses we conducted, and the cost-effectiveness was estimated to be 183 US dollars. CONCLUSIONS: We found a significant shift in prescribing of antihypertensive drugs towards the use of thiazides in our trial. A major reason to promote the use of thiazides is their lower price compared to other drugs. The cost of the intervention was more than twice the savings within the time frame of our study. However, we predict modest savings over a 2-y period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness and efficiency of guideline dissemination and implementation strategies
Grimshaw, J., Thomas, R., MacLennan, G., Fraser, C., Ramsay, C., Vale, L., Whitty, P., Eccles, M., Matowe, L., Shirran, L., et al. (2004) · Health Technology Assessment · doi:10.3310/hta8060 · Cited by 3,044 · cited 1×
“The authors of a recent systematic review of guideline implementation strategies found that ‘‘relatively few studies considered any costs other than those of treatment and its consequences’’ [2].”
BackgroundEffectiveness and efficiency of guideline dissemination and implementation strategies
Grimshaw, J. M., Thomas, R. E., MacLennan, G., Fraser, C., Ramsay, C. R., Vale, L., Whitty, P., Eccles, M. P., Matowe, L., Shirran, L., et al. (2005) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462305290190 · Cited by 864
Rational prescribing in primary care (RaPP): a cluster randomized trial of a tailored intervention
Fretheim, A., Oxman, A. D., Håvelsrud, K., Treweek, S., Kristoffersen, D. T., & Bjørndal, A. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030134 · Cited by 99
Self-citation
Cited by
Educational outreach visits: effects on professional practice and health care outcomes
O'Brien, M. A., Rogers, S., Jamtvedt, G., Oxman, A. D., Odgaard-Jensen, J., Kristoffersen, D. T., Forsetlund, L., Bainbridge, D., Freemantle, N., Davis, D., et al. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000409.pub2 · Cited by 1,279
Self-citationEffect of Clinical Decision-Support Systems: A Systematic Review
Bright, T. J., Wong, A., Dhurjati, R., Bristow, E., Bastian, L., Coeytaux, R. R., Samsa, G., Hasselblad, V., Williams, J. W., Musty, M. D., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-1-201207030-00450 · Cited by 1,200
Physician Awareness of Drug Cost: A Systematic Review
Allan, G. M., Lexchin, J., & Wiebe, N. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040283 · Cited by 292
Rational prescribing in primary care (RaPP): a cluster randomized trial of a tailored intervention
Fretheim, A., Oxman, A. D., Håvelsrud, K., Treweek, S., Kristoffersen, D. T., & Bjørndal, A. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030134 · Cited by 99
“]. We did not find our intervention to be effective for other behaviors. We report on the cost effectiveness of our intervention in a companion article [”
Self-citationEconomic evaluations of audit and feedback interventions: a systematic review
Moore, L., Guertin, J. R., Tardif, P.-A., Ivers, N. M., Hoch, J., Conombo, B., Antony, J., Stelfox, H. T., Berthelot, S., Archambault, P., et al. (2022) · BMJ Quality & Safety · doi:10.1136/bmjqs-2022-014727 · Cited by 33
Metadata
- Authors
- Fretheim, A., Aaserud, M., & Oxman, A. D.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2006-06-06
- Volume
- 3
- Issue
- 6
- Pages
- e216
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2076415548
- Cited by
- 43
- References
- 4
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.